Alterity Therapeutics Ltd (ATHE)
Alterity Therapeutics Ltd is an Australia-based biotechnology company focused on researching and developing therapies for neurological disorders, including Alzheimer’s disease, Huntington disease, Parkinson’s disease, and multiple system atrophy. The company’s lead candidate, ATH434, is a small molecule program that has completed a Phase I clinical trial for Parkinson’s disease. Alterity is also advancing ATH434-201 and ATH434-202, both in Phase II trials for multiple system atrophy, with the latter also examining biomarkers associated with disease progression. Founded in 1997 and formerly known as Prana Biotechnology Limited, the company adopted its current name in April 2019. The listed security is a depositary receipt representing common stock on NASDAQ.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ATHE
|
$3.07
|
-21.6% Downside
|
Overvalued
|
$13.25
|
238.0% Upside
|
Bargain
|
Fair
|
0.0%
|
October 28, 2026
|
2.3x
|
27.5x
|
70.768 M
|
43.036 M
|
0.2%
|
79.8%
|
1.9
|
96.2%
|
